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Background: A 6-mg dose of SC sumatriptan is the most efficacious and fast-acting acute treatment for migraine,
but a 3-mg dose of SC sumatriptan may improve tolerability while maintaining efficacy.
Methods: This randomized, double-blind, crossover study compared the efficacy and tolerability of 3 mg subcutaneous
(SC) sumatriptan (DFN-11) with 6 mg SC sumatriptan in 20 adults with rapidly-escalating migraine attacks. Eligible subjects
were randomized (1:1) to treat 1 attack with DFN-11 and matching placebo autoinjector consecutively or 2 DFN-11
autoinjectors consecutively and a second attack similarly but with the alternative dose (3 mg or 6 mg).
Results: The proportions of subjects who were pain-free at 60 min postdose, the primary endpoint, were similar
following treatment with 3 mg SC sumatriptan and 6 mg SC sumatriptan (50% vs 52.6%, P = .87). The proportions of
subjects experiencing pain relief (P ≥ .48); reductions in migraine pain intensity (P ≥ .78); and relief from nausea,
photophobia, or phonophobia (P ≥ .88) with 3 mg SC sumatriptan and 6 mg SC sumatriptan were similar, as were the
mean scores for satisfaction with treatment (M = 2.6 vs M = 2.4, P = .81) and the mean number of rescue medications
used (M = .11 vs M = .26, P = .32). The most common adverse events with the 3- and 6-mg doses were triptan
sensations — paresthesia, neck pain, flushing, and involuntary muscle contractions of the neck — and the incidence of
adverse events with both doses was similar (32 events total: 3 mg, n = 14 [44%]; 6 mg, n = 18 [56%], P = .60). Triptan
sensations affected 4 subjects with the 6-mg dose only, 1 subject with the 3-mg dose only, and 7 subjects with both
sumatriptan doses. Chest pain affected 2 subjects (10%) treated with the 6-mg dose and no subjects (0%) treated with
the 3-mg dose of DFN-11. There were no serious adverse events.
Conclusions: The 3-mg SC dose of sumatriptan in DFN-11 provided relief of migraine pain and associated symptoms
comparable to a 6-mg SC dose of sumatriptan. Tolerability was similar with both study medications; DFN-11 treatment
was associated with fewer triptan sensations than the 6-mg dose. DFN-11, with its 3-mg dose of sumatriptan, may be a
clinically useful alternative to higher-dose autoinjectors.
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Migraine is a chronic neurologic disease characterized by
recurrent episodes of headache associated with a wide
array of disruptive symptoms, including photophobia,
phonophobia, nausea, and/or vomiting [1, 2]. It is the
most common neurological disease for which people seek
medical consultation, affecting about 12% of adults in the
United States, three quarters of them women [3–5].
Nearly all migraineurs (93%) have some degree of attack-
related impairment, and more than half (54%) are severely
impaired by their attacks [3]; among women, migraine
ranks in the top 10 causes of disability worldwide [6].
Because migraine is heterogeneous and often spans
decades of patients’ lives, clinical presentations and acute
treatment needs can vary considerably over time, and
patients often require different formulations of acute
medications to optimize treatment outcomes [7]. This is
particularly true when attacks are severe, accompanied by
nausea and vomiting, or rapid in onset, and parenteral for-
mulations are needed to control symptoms.
Sumatriptan — the first, most widely studied, and most
frequently prescribed member of the “triptan” class of
medications [2, 8, 9] — is available as a subcutaneous (SC)
injection, intranasal spray, oral tablet, and, in some coun-
tries, a rectal suppository. The 6 mg SC injection has long
been considered optimal for acute therapy of migraine [2];
in large double-blind, randomized, placebo-controlled
clinical trials, 70% of subjects with moderate to severe at-
tacks experienced pain relief within 1 h of dosing, and
50% were pain-free [10, 11]. The rapid onset of action of
SC sumatriptan is especially important for patients whose
attacks become disabling soon after onset [12].
Despite its well-established efficacy and rapid onset of
action, sumatriptan 6 mg SC injection has a suboptimal
tolerability profile. Many patients (42%) experience
triptan sensations [13], such as paresthesia and chest
symptoms, that appear to be dose-related [14]. Concerns
about drug-related adverse events (AEs), which have
caused two thirds of migraine patients to delay or avoid
taking a prescription medication, may help to explain
why fewer than 10% of eligible migraine patients use the
SC formulation of sumatriptan to treat their disease
[15]. These concerns can be particularly important in
patients with various types of medical conditions (eg,
cardiovascular and cerebrovascular disease and some
psychiatric illnesses) and/or treated with various medica-
tions (eg, monoamine oxidase inhibitors and selective
serotonin reuptake inhibitors) [9]. Based on previous
research [16], we hypothesized that a formulation using
a lower doses of sumatriptan may improve safety and
tolerability while maintaining efficacy similar to 6 mg SC
sumatriptan, and that a 3-mg dose may be sufficient in
many patients. The objective of this exploratory study was
to compare the efficacy and tolerability of 3 mg SCsumatriptan (using DFN-11 and matching placebo autoin-
jectors consecutively) with 6 mg SC sumatriptan (using 2
DFN-11 autoinjectors consecutively) for the acute
treatment of episodic migraine attacks.
Methods
This was a double-blind, crossover, pilot study conducted
at a single study center (Clinvest; Springfield, MO). The
study compared a 3-mg SC dose of sumatriptan with the
commonly prescribed 6-mg SC dose in 19 subjects. The
protocol was approved by the Sterling Institutional Review
Board, and the study was conducted in compliance with
good clinical practice and in accordance with the ethical
principles set forth in the Declaration of Helsinki. Prior to
the initiation of any study-specific procedures, investiga-
tors explained the nature of the study to the subjects, and
subjects provided informed consent. The first subject was
enrolled on 15 September 2015, and the study was
completed on 14 April 2016. Additional information
about this trial is available online at ClinicalTrials.gov
(Identifier: NCT02571049).
Study conduct
To participate, subjects recruited from the clinic and
general population had to satisfy a range of inclusion
and exclusion criteria (Table 1). The research coordin-
ator and investigator initially evaluated eligibility and
obtained informed consent. Final eligibility was deter-
mined by the investigator, and the research coordinator
completed the enrollment process.
The study consisted of 4 visits: screening, randomization,
treatment crossover, and end-of-study. Subjects treated up
to 2 attacks within 4 weeks. At the screening visit, subjects
provided a detailed medical and headache/migraine
history, a physical examination was performed, labora-
tory assessment samples (ie, hematology, serum chemistry,
urine analysis, serology, urine drug screen) were obtained,
inclusion/exclusion criteria were verified, and a 12-lead
electrocardiogram (ECG) was completed. Eligible subjects
returned to the site with 14 days of the screening visit and
were trained in the appropriate use of the autoinjector
device and given printed instructions to take home that
reinforced correct DFN-11 administration.
Subjects were divided into 1 block and randomized
(1:1) to receive 3 mg SC sumatriptan (using DFN-11 and
matching placebo autoinjectors consecutively) or 6 mg SC
sumatriptan (using 2 DFN-11 autoinjectors consecutively)
in a crossover design and were dispensed the first treat-
ment in the sequence. The randomization scheme was
generated by study personnel with no subject inter-
action or other monitoring roles using an online tool
(http://www.randomization.com); it was provided to
the drug packing company, which used it to prepare
and pre-label the kits with sequential numbers. The
Table 1 Inclusion and exclusion criteria
Inclusion Exclusion
ICHD-3-beta episodic migrainea Unable to distinguish migraine from other primary headache conditions
Onset of migraine before age 50 15 or more headache days per month
≥3-month history of 2–8 attacks/month; ≥75% of
attacks progress to moderate or severe pain and/or
nausea within 2 h (ie, rapidly-escalating)
Opioid usage >10 days in the 30 days before screening
Acute headache medication on≤14 days/month in
the 3 months prior to enrollment
Use of MAO-A inhibitors within 28 days of randomization
No sumatriptan injections for≥3 months History of hemiplegic/basilar migraine; epileptogenic conditions;
symptoms or signs of ischemic cardiac, cerebrovascular or peripheral
vascular syndromes, or uncontrolled hypertension
If taking migraine prophylaxis, stable for 30 days
before and throughout the study
Drug or alcohol abuse within the previous 2 years
Females: negative urine pregnancy test at screening,
effective birth control, or surgically sterile or
postmenopausal for≥1 year before enrollment
Systemic disease or neurological or psychiatric conditionb
Willing to read and comprehend written instructions
and internet access for electronic diary
Investigational medication ≤30 days before randomization
Sign informed consent document Positive urine drug screen for recreational drugs, marijuana, or prescription
drugs not explained by stated concomitant medications
Clinical laboratory or ECG abnormality
Fridericia’s corrected QT interval >450 msec
Creatinine >2 mg/dl; serum total bilirubin >2.0 mg/dL
Serum AST, ALT, or alkaline phosphatase >2.5 times ULN
Rebound headache from caffeine usageb
ICHD International Classification of Headache Disorders, MAO-A monoamine oxidase A, ECG electrocardiogram, AST aspartate aminotransferase, ALT, ULN upper
limit of normal
aWith or without aura
bContraindicated participation in the opinion of the investigator
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lowest kit number available.
Diary instruction was provided, and subjects were
encouraged to treat an attack within 1 h of onset of head-
ache. They were asked not to use rescue medication until
at least 120 min postdose. After subjects treated the first
attack, they returned to the clinic for re-evaluation and
treatment crossover. Before treating a second attack,
subjects had to be pain-free for a minimum of 24 h. The
end-of-study visit occurred within 7 days after treatment
of the second attack or within 4 weeks of randomization,
whichever came first. At the end-of-study visit, the sub-
ject’s diary information was reviewed, and all end-of-study
visit procedures were performed.
Adverse events were monitored from the time subjects
gave informed consent until the follow-up visit; physical
examinations, vital sign measurements, ECGs, and la-
boratory assessments were performed at designated
visits throughout the study period.
Assessments
Efficacy
The prospectively defined primary efficacy endpoint was
the proportion of subjects reporting freedom from pain at60 min postdose; pain freedom was defined as a headache
pain severity rating of 0 (no pain). Secondary endpoints
included pain relief, pain freedom, and headache severity
at 30, 60, 90, and 120 min postdose, proportion of subjects
with relief of associated migraine symptoms (ie, nausea,
photophobia, and phonophobia) at 60 min postdose, sub-
ject satisfaction with treatment, and use of rescue medica-
tion from 2 to 24 h postdose. Pain relief was defined as a
1-point reduction in headache pain intensity, which was
rated on a 4-point Likert scale where 0 = no pain, 1 =
mild pain, 2 = moderate pain, and 3 = severe pain. Relief
of the associated symptoms of nausea, photophobia, and
phonophobia was defined as a 1-point reduction in symp-
tom severity where 0 = no symptom, 1 = mild, 2 =
moderate, and 3 = severe. Subject satisfaction with treat-
ment was based on a 7-point Likert Scale, with 1 being
very satisfied and 7 being very dissatisfied. Use of rescue
medication was calculated by totaling the number of
rescue medications used from 2 to 24 h postdose.
The primary and most of the secondary endpoint data
were derived from an online headache e-diary. Daily diary
assessments included onset and duration of headache,
severity of pain at the time of onset and at treatment,
acute headache pain medication(s) usage, study drug
Screened
n =  24
Failed to Meet 
Inclusion/Exclusion Criteria







a1 subject randomized to 6 mg only treated 1 attack
Fig. 1 Subject disposition
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ject satisfaction with treatment.
Tolerability
Tolerability was assessed by comparing AEs occur-
ring up to 24 h postdose. Safety measures included
AEs, physical examinations, vital signs, ECG readings, and
laboratory assessments (hematology, serum chemistry, urine
analysis). Adverse events were coded with the Medical Dic-
tionary for Regulatory Activities (MedDRA, version 17.0)
and classified by date of onset, duration, frequency, severity,
and relationship to study medication. The classification of
AEs as triptan sensations was determined by principal
investigator. Spontaneously reported AEs were recorded for
up to 5 days after the last dose of study drug; AEs deter-
mined as serious were recorded for up to 30 days.
Statistical analysis
All statistical tests were 2-tailed, and an alpha of .05 was
used to determine statistical significance. Descriptive
statistics established baseline characteristics and AE
frequency. Data for the primary endpoint was analyzed
via chi-squared analyses; the secondary outcome mea-
sures were analyzed with a 2-tailed Repeated Measures
analysis of variance (ANOVA), chi-squared, and/or
independent or dependent t-tests, as appropriate. All
ANOVAs were followed by univariate post hoc tests, as
appropriate, and multiple comparison adjustments were
made as needed. A last observation carried forward
method was used to impute missing values within a sin-
gle headache diary attack.
Efficacy analyses were performed on a modified intent-
to-treat population, which included all randomized
subjects who received at least 1 dose of study drug and
obtained at least 1 endpoint measurement (mean change
from baseline in the number of hours with headaches)
after treatment. The safety population included all
randomized subjects.
Results
Twenty-four subjects were screened, 20 subjects were ran-
domized (1 never treated), and 19 subjects treated at least
1 migraine attack (Fig. 1). The study population was 80%
female and 95% Caucasian, with a mean age of 39.8 years.
At baseline, subjects were experiencing 5 migraine days
and 6.8 headache days per month on average (Table 2).
The proportion of subjects who were pain-free at
60 min postdose, the primary efficacy endpoint, was
50.0% for 3 mg SC sumatriptan and 52.6% for 6 mg
SC sumatriptan (P = .87), as shown in Fig. 2. Pain-
free responses to 3 mg SC sumatriptan and 6 mg SC
were already apparent at 30 min (22.2% vs 15.8%, re-
spectively; P = .62). At 90 min, 66.7% vs 68.4% of
subjects were pain-free (P = .91), and these responseswere sustained to 120 min postdose (66.7% vs 68.4%;
P = .91).
Eighty-three percent of subjects experienced pain
relief with 3 mg SC sumatriptan at 60, 90, and
120 min postdose; the corresponding pain relief rates
with the 6-mg dose, 73.7% (P = .48), 79.0% (P = .73),
and 89.5% (P = .59), were not significantly different at
any timepoint (Fig. 3). With a mean (SD) predose
pain intensity of 2.1 (.6), reductions in migraine pain
intensity after treatment with 3 and 6 mg SC suma-
triptan were comparable at all time points (P = .78)
over the 2-h assessment period (Fig. 4).
At 60 min postdose (Fig. 5), there were no significant
differences between 3 and 6 mg SC sumatriptan in the
proportions of subjects who experienced relief from
nausea (P = .91), photophobia (P = .89), or phonophobia
(P = .88). The mean number of rescue medication doses
used over the course of the study period was not signifi-
cantly different when subjects treated with 3 mg or 6 mg
SC sumatriptan (M = .11 vs M = .26). Subjects were
similarly satisfied with either treatment, with no signifi-
cant difference in mean scores for 3 and 6 mg SC suma-
triptan (M = 2.6 vs M = 2.4).
Tolerability
In the safety population (N = 20), 80% of subjects (16/20)
experienced a total of 50 AEs. The overall incidence of
AEs with DFN-11 (.72) and 6 mg SC sumatriptan (.74)
was comparable (P = .97), and the most common AEs
were triptan sensations: paresthesia (30%, 6/20), neck pain











Migraine Days/Month 5.0 (3.7)
Headache Days/Month 6.8 (1.7)
aValues are mean (SD)
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involuntary muscle contractions of the neck (10%, 2/20),
and vomiting (10%, 2/20). As shown in Table 3, there were
no significant differences in the frequency (14 vs 18
events, P = .60), duration (27 vs 64 min, P = .43), and
severity (1.29 vs 1.28 [0–3 scale], P = .97) of triptan
sensations with DFN-11 and 6 mg SC sumatriptan.
Of the 12 subjects who reported triptan sensation
AEs, 7 subjects experienced them with DFN-11 and 6 mg
SC sumatriptan, 1 subject experienced them only after
DFN-11, and 4 subjects experienced them only following
6 mg SC sumatriptan. There were no meaningful changes
from baseline in vital signs, ECGs, or laboratory assess-
ments, and no serious AEs were reported.
Discussion
Migraineurs consistently rate rapid onset of pain relief






































Fig. 2 Pain freedom at 30, 60, 90, and 120 min postdosea,b. Legend: SC, su
b1 subject randomized to 6 mg only treated 1 attackattributes of acute migraine medication [17, 18]. With
an onset of action of approximately 10 min and unparal-
leled relief of migraine headache and associated
symptoms [14], SC sumatriptan has been the most
effective acute migraine therapy since its introduction
nearly 25 years ago [2]. The primary limitations to its
use as an acute therapy are medication-related AEs.
Understanding the tolerability of treatment is important
as to why migraine patients settle for less effective alter-
natives [16]. For many, the relatively high likelihood of
experiencing triptan sensations is a barrier to effective
parenteral migraine-specific therapy. Paradoxically, the
characteristics believed to be responsible for the high
rate of efficacy seen with the injectable forms — faster
bioavailability and greater systemic exposure compared
with oral formulations — may also contribute to the
relatively high rate of triptan sensations. It has been
suggested that novel sumatriptan formulations with
pharmacokinetics similar to SC sumatriptan are promis-
ing for use in clinical practice [2].
In this study of subjects with rapidly-escalating attacks of
episodic migraine, treatment with DFN-11, a 3 mg SC su-
matriptan autoinjector, was comparable to SC sumatriptan
6 mg on all clinically relevant efficacy endpoints. The pain-
free results at 60 min postdose suggest that DFN-11 may
be a fast-acting alternative to commercial formulations of
injectable sumatriptan, especially for patients who awaken
with full-blown attacks already in progress [19]. In our
study, the lower, 3-mg dose of sumatriptan in DFN-11 did
not appear to impede the overall therapeutic effect, and
DFN-11 maintained an efficacy timecourse similar to SC
sumatriptan 6 mg — a finding in accord with a previous re-
port comparing 3 and 6 mg SC sumatriptan [20].
The most common AEs were triptan sensations known
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Fig. 3 Pain relief at 30, 60, 90, and 120 min postdosea. Legend: SC, subcutaneous. a1 subject randomized to 6 mg only treated 1 attack
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seen in previous studies of the SC formulation of suma-
triptan. Notably, while most subjects experienced symp-
toms with both sumatriptan doses, fewer subjects had
triptan sensations only after treatment with the 3-mg
dose than with the 6-mg dose. In addition, the triptan
sensation of chest pain, which has been shown to cause
up to 10% of sumatriptan-treated patients to discontinue
therapy [21] and may lead to substantially increased
medical costs for migraine care [22], was not observed
after the 3-mg dose of DFN-11 treatment. With the
6 mg SC sumatriptan treatment, 10% of subjects were
affected, and the mean duration of the events exceeded
6 h. The implications of these findings deserve to be



















P < .001 for 
n = 18
P = .78 for g
Fig. 4 Pain intensity at predose, 30, 60, 90, and 120 min postdosea,b,c. Lege
attack. bRepeated Measures ANOVA revealed an insignificant group and tim
time was found for pain intensity scores: F(2.43, 85.02) = .61, P < .001While the results with DFN-11 are similar in many
aspects to those seen in previous dose-comparing stud-
ies of SC sumatriptan, there may be clinically important
differences. For example, an open-label trial comparing
the 3 and 6 mg SC doses (in which 80% of subjects pre-
ferred the 3-mg dose) found, as in the current study,
that the proportions of subjects with pain-free responses
were similar between the 2 doses at 1 and 2 h after treat-
ment [20]. However, the 1-h pain relief rate for the 3-mg
SC dose in this study exceeded previous reports for the
6-mg SC dose at that timepoint (83% vs 70%) [14]. The
higher treatment response may reflect the benefits of
treating at the first sign of migraine pain, as subjects
in the earlier studies [14, 20] waited for pain to reach
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Fig. 5 Proportions of subjects experiencing relief from symptoms associated with migraine at 60 min postdose.a Legend: SC, subcutaneous.
a1 subject randomized to 6 mg only treated 1 attack. b3 mg n = 8; 6 mg n = 10. c3 mg n = 9; 6 mg n = 11. d3 mg n = 10; 6 mg n = 9
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[14, 20].
The current study has strengths and limitations. Its
main strength is its originality; this is the first well-
controlled study to compare the efficacy and tolerabil-
ity of 3- and 6-mg SC doses of sumatriptan. Another
strength is that because subjects in this study treated
at the first sign of migraine, which can prevent the
development of central sensitization [23] and optimize
pain-free efficacy [24–26], the performance of DFN-Table 3 Triptan sensations after treatment with 3 and 6 mg SC sum





Paresthesia 5 (15.63) 13.0 (.01)
Neck Pain 4 (12.50) 12.0 (.01)
Flushing 2 (6.25) 25.0 (.01)
Muscle Contractions (Neck)c 1 (3.13) 44 (N/A)
Chest Pain 0 (0) —
Disorientation 0 (0) —
Dizziness 0 (0) —
Myalgia 0 (0) —
Tinnitus 0 (0) —
Vomiting 0 (0) —
Hyperhidrosis 1 (3.13) 38 (N/A)
Malaise 1 (3.13) 130 (N/A)
Total 14 (44)d 27 (33.12)e
SC subcutaneous
aMean (SD)
bAssessed on a 3-point Likert scale: mild = 1, moderate = 2, and severe = 3
cInvoluntary
dP = .60 vs 6 mg
eP = .43 vs 6 mg
fP = .97 vs 6 mg11 was assessed under conditions that simulate actual
treatment scenarios. Limitations of the study include
the lack of power and sample size calculation, as well
as the small sample size, which restrict the validity
and generalizability of results. It is also possible that
outcomes might have been affected by subjects’ using
2 consecutive injections to provide a 6-mg dose of
sumatriptan, but there is no evidence that this
method of administering study medication influences
response to sumatriptan.atriptan









1.20 (.45) 4 (12.50) 20.0 (.01) 1.0 (0.0)
1.25 (.50) 3 (9.38) 11.0 (.00) 1.0 (0.0)
1.50 (.71) 2 (6.25) 11.0 (.01) 1.50 (.71)
1.0 (N/A) 2 (6.25) 47 (N/A) 1.50 (.71)
— 2 (6.25) 374 (.35) 2.0 (1.41)
— 1 (3.13) 19 (N/A) 1.0 (N/A)
— 1 (3.13) 20 (N/A) 1.0 (N/A)
— 1 (3.13) 44 (N/A) 1.0 (N/A)
— 1 (3.13) 41 (N/A) 1.0 (N/A)
— 1 (3.13) 41 (N/A) 1.0 (N/A)
1.0 (N/A) 0 (0) — —
2.0 (N/A) 0 (0) — —
1.29 (.47)f 18 (56) 64 (167.10) 1.28 (.57)
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In this randomized, double-blind, crossover pilot study
comparing 3 mg SC sumatriptan with 6 mg SC sumatrip-
tan for acute treatment of rapidly-escalating attacks of epi-
sodic migraine, both the 3- and 6-mg doses demonstrated
comparable efficacy on all efficacy endpoints. The 3-mg
and 6-mg SC doses were also similar on safety parameters,
but DFN-11 was associated with better tolerability, as
shown by a lower incidence of triptan sensation AEs. Of
particular interest was the lack of chest pain as an AE with
DFN-11. These preliminary results need to be confirmed
in larger clinical studies.
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